PTO/SB/08A (08-03)

Approved for use through 07/31/2005. OMB 0651-0031

U.S. Patent and Trademank Office; U.S. DEPARTMENT OF COMMERCE

1 Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Ментония 249/PTO

Sheet 1

				DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number  Number-KingCoge <sup>2</sup> // 5 <sup>comb</sup> /7 5 2	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whei Relevant Passages or Releva Figures Appear			
/CC/		US- 5+84 <b>8+75</b> 2	12-15-1998	Grunenberg et al.				
/CC/		<sup>US-</sup> 5,157,117	10-20-1992	Takagi et al.				
		US-						
		US-						
		US-						
		US-						
		US-						
	T -	US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Pesseges Or Relevant Figures Appear		
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (# known)	MM-DD-YYYY	The production of the position			
/CC/		EP 0 350 733 B1	01-17-1990	Bayer AG			
		EP 0 629 621 A1	12-21-1994	Chugai Seiyaku		Γ	
		WO 99/26940	06-03-1999	Bayer AG		Г	
		EP 0 657 448	06-14-1995	Bayer AG			
/CC/		EP 0 550 903	07-14-1993	Bayer AG			
						t	

Signatu		/Celia Chang/									Date Cons	sidered		10/29/2008								
EXAM	NER: Initial	if reference	considere	d, whether	er or no	t citation	is in	confor	nance	with	MPEP	609.	Draw	line	through	citatio	on if	not in	1 conf	omance	and	not

EXAMPLE: filled in teleprited controllered, remains on low causes to an incommensure arts must considered, include copy of this form with here dominantion to applicant. "Applicants using us indicated degination number (optional)." See Kinds Codes of USPTO Pattert Documents at two was proposed to the proposed of the p

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to fit (and by the USFFO to proceed) an application. Confidentially is governed by 35 U.S. C. 22 and 37 CFR 1.14. This collection is estimated to take 2 to compete, uncluding gathering, preparing, and submitting the completed application form to the USFFO. Three will vary depending upon the individual case, A<sub>1</sub> y comments on the amount of the year required to complete this form and reduce suppression for reducing this burden is should be sent to the Chief Information Critical U.S. Patient and Trademark Office, P.O. Box 1450, Alexandris, VA 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND